Your browser doesn't support javascript.
loading
Night-Time Apomorphine Infusion: Who Are the Best Candidates?
Cochen De Cock, Valérie; Dodet, Pauline; Leu-Semenescu, Smaranda; Aerts, Cécile; Abril, Beatriz; Castelnovo, Giovanni; Landragin, Nicolas; Drapier, Sophie; Olivet, Hélène; Corbillé, Anne-Gaëlle; Leclair-Visonneau, Laurène; Anheim, Mathieu; Vidailhet, Marie; Arnulf, Isabelle; Doulazmi, Mohamed; Roze, Emmanuel.
Afiliação
  • Cochen De Cock V; Sleep and Neurology Department Beau Soleil Clinic Montpellier France.
  • Dodet P; EuroMov Digital Health in Motion Univ Montpellier, IMT Mines Alès Montpellier France.
  • Leu-Semenescu S; Sleep Disorders Unit Pitié-Salpêtrière University Hospital Paris France.
  • Aerts C; Sleep Disorders Unit Pitié-Salpêtrière University Hospital Paris France.
  • Abril B; Sleep and Neurology Department Beau Soleil Clinic Montpellier France.
  • Castelnovo G; EuroMov Digital Health in Motion Univ Montpellier, IMT Mines Alès Montpellier France.
  • Landragin N; Sleep Department University Hospital of Nîmes Nîmes France.
  • Drapier S; Department of Neurology University Hospital of Nîmes Nîmes France.
  • Olivet H; Clinique du Millénaire Montpellier France.
  • Corbillé AG; Department of Neurology Pontchaillou INSERM CIC1414 Rennes France.
  • Leclair-Visonneau L; Sleep Department Polyclinique Rennes Saint-Laurent Rennes France.
  • Anheim M; Neurology Department University Hospital of Nantes, INSERM, CIC 1413 Nantes France.
  • Vidailhet M; Clinical Neurophysiology Department University Hospital of Nantes, INSERM U1235, Nantes University Nantes France.
  • Arnulf I; Department of Neurology University Hospital of Strasbourg Strasbourg France.
  • Doulazmi M; Genetic Institute and Molecular and Cellular Biology (IGBMC), INSERM-U964/CNRS-UMR7104/ Strasbourg University Illkirch France.
  • Roze E; AP-HP, Salpetriere Hospital, DMU Neuroscience 6 Paris France.
Mov Disord Clin Pract ; 10(8): 1192-1197, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37635769
ABSTRACT

Background:

We recently demonstrated in a randomized controlled trial (APOMORPHEE, NCT02940912) that night-time only subcutaneous apomorphine infusion improves sleep disturbances and insomnia in patients with advanced Parkinson's disease and moderate to severe insomnia.

Objectives:

To identify the best candidates for receiving night-time only subcutaneous apomorphine infusion in routine care.

Methods:

In this post-hoc analysis of APOMORPHEE, we compared the characteristics of patients according to whether they chose to continue night-time only subcutaneous apomorphine infusion at the end of the study period or not.

Results:

Half of the patients (22/42) chose to continue the treatment. Off duration (day or night), painful Off dystonia, and insomnia severity at baseline were associated with night-time only apomorphine continuation. Multivariate analysis retained only Off duration as an independent predictor of continuation.

Conclusions:

The best candidates for night-time only apomorphine are patients with severe and prolonged Off periods (day or night) and severe insomnia.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article